Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apremilast in early oligoarticular psoriatic arthritis
NL-OMON48290Phase 4Withdrawn
- Sponsor
- Celgene Corporation
- Start
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in psoriatic arthritis (PsA) comparing Apremilast plus background therapy with Placebo plus background therapy (2 arms). Primary endpoint: Modified Minimal Disease Activity (MDA-Joints). Planned start Nov 2018; status: withdrawn.
02
Drugs
apremilast
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NL-OMON48290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48290.